Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

CSTL Castle Biosciences

Watchlist
21.850
-1.160-5.04%
Trading Session 06/30 15:42 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
22.846
Open
22.720
Turnover
2.60M
Low
21.785
Pre Close
23.010
Volume
117.33K
Market Cap
573.80M
P/E(TTM)
Loss
52wk High
78.585
Shares
26.26M
P/E(Static)
Loss
52wk Low
15.580
Float Cap
541.35M
Bid/Ask %
-20.00%
Historical High
107.690
Shs Float
24.78M
Volume Ratio
0.22
Historical Low
15.260
Dividend TTM
--
Div Yield TTM
--
P/B
1.44
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.47%
Amplitude
4.61%
Avg Price
22.171
Lot Size
1
Float Cap
541.35M
Bid/Ask %
-20.00%
Historical High
107.690
Shs Float
24.78M
Volume Ratio
0.22
Historical Low
15.260
Dividend TTM
--
P/B
1.44
Dividend LFY
--
Turnover Ratio
0.47%
Amplitude
4.61%
Avg Price
22.171
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
CEO: Maetzold, Derek J.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top